Australia. The Adverse Drug Reactions Advisory Committee (ADRAC) has received 130 adverse drug reaction reports involving reboxetine (Edronax), including 41 reports of genitourinary disorders that developed within 5 weeks of initiating treatment. In 26 reports, patients experienced symptoms that were consistent with urinary obstruction (hesitancy, retention, dribbling post-micturition and reduced urine flow) and, of those, all but six involved male patients. ADRAC has also received 22 reports of male sexual dysfunction, including erectile dysfunction (n = 4), pain or swelling of the external genitalia or testicles (10) and ejaculation disorders (7), and two reports of women with increased libido. Reboxetine is a selective noradrenaline reuptake inhibitor. ADRAC recommends that, soon after commencing reboxetine treatment, patients should be asked about

symptoms of sexual dysfunction or urinary obstruction.

Reference:

Adverse Drug Reactions Advisory Committee. Genitourinary symptoms with reboxetine. Australian Adverse Drug Reactions Bulletin, June 2005, 24(3):10.